Phase II controlled trial of post-exposure immunization with recombinant gp160 versus antiretroviral therapy in asymptomatic HIV-1-infected adults

AIDS

Volumn 12, Issue 5, 1998, Pages 473-480

  Pontesilli, Oscar ^a   Guerra, Emma C ^a   Ammassari, Adriana ^b   Tomino, Carlo ^c   Carlesimo, Maurizio ^a   Antinori, Andrea ^b   Tamburrini, Enrica ^b   Prozzo, Alessandra ^a   Seeber, Angela C ^c   Vella, Stefano ^c   Ortona, Luigi ^b   Aiuti, Fernando ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

gp160; Immunotherapy; Zidovudine

Indexed keywords

ALUMINUM POTASSIUM SULFATE; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; GLYCOPROTEIN GP 160; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PLACEBO; VIRUS ENVELOPE PROTEIN; ZIDOVUDINE;

ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOTHERAPY; INTRAMUSCULAR DRUG ADMINISTRATION; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NONHUMAN; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE; VIREMIA;

ADOLESCENT; ADULT; AIDS VACCINES; CD4 LYMPHOCYTE COUNT; CD8-POSITIVE T-LYMPHOCYTES; COMBINED MODALITY THERAPY; DOUBLE-BLIND METHOD; FEMALE; HIV ENVELOPE PROTEIN GP160; HIV INFECTIONS; HIV-1; HUMANS; LYMPHOCYTES; MALE; MIDDLE AGED; RNA, VIRAL; TIME FACTORS; VACCINES, SYNTHETIC; VIREMIA; ZIDOVUDINE;

EID: 6844252887     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199805000-00008     Document Type: Article

References (24)

1. Salk J: Prospects for the control of AIDS by immunizing seropositive individuals. Nature 1987, 327:473-476.
2. Levine AM, Groshen S, Allen J, et al.: Initial studies on active immunization of HIV-infected subjects using a gp120-depleted HIV-1 immunogen: long-term follow-up. J Acquir Immune Defic Syndr Hum Retrovirol 1996, 11:351-364.
3. Redfield RR, Birx DL, Ketter N. et al.: A Phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. N Engl J Med 1991, 324:1677-1684.
4. Wahren B, Bratt G, Persson C, et al.: Improved cell-mediated immune responses in HIV-1-infected asymptomatic individuals after immunization with envelope glycoprotein gp160. J Acquir Immune Defic Syndr 1994, 172:367-369.
5. 3 CD4 T lymphocytes. J Infect Dis 1996, 173:1336-1346.
6. Centers for Disease Control: 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1993, 41 (RR-17):1-19.
7. Pontesilli O, Carlesimo M, Varani AR, et al.: HIV-specific lymphoproliferative responses in asymptomatic HIV-infected individuals. Clin Exp Immunol 1995, 100:419-424.
8. Pontesilli O, Varani AR, Carlesimo M, et al.: HIV-1 Env specific cytotoxicity in patients with asymptomatic HIV disease before and after immunization with recombinant gp160. Int J Immunopathol Pharmacol 1994, 7:251-260.
9. Pandolfi F, Oliva A, Sacco G, et al.: Fibroblast-derived factors preserve viability in vitro of mononuclear cells isolated from subjects with HIV-1 infection. AIDS 1993, 7:323-329.
10. Carlesimo M, Pontesilli O, Guerra EC, et al.: Long-term evaluation of cellular immunity during antiretroviral therapy and immunization with HIV-1 Env glycoprotein in HIV-1 infected individuals. J Infect Dis 1997, 176:904-912.
11. Kundu SK, Katzenstein D, Moses LE, Merigan TC: Enhancement of human immunodeficiency virus (HIV)-specific CD4+ and CD8+ cytotoxic T-lymphocyte activities in HIV-infected asymptomatic patients given recombinant gp160 vaccine. Proc Natl Acad Sci USA 1992, 89:11204-11208.
12. Tsoukas CM, Raboud J, Schlench W, et al.: Active immunization of patients with HIV infection: a controlled study of the effect of VaxSyn on progression of immune deficiency. XI International Conference on AIDS. Vancouver, July 1996 [abstract TuA274].
13. Birx DL, Davis C, Ruiz N, et al.: Results of a Phase II, double-blinded, multicenter, placebo controlled HIV therapeutic vaccine trial. XI International Conference on AIDS. Vancouver, July 1996 [abstract TuA275].
14. Eron JJ, Ashby MA, Giordano MF, et al.: Randomised trial of MNrgp120 HIV-1 vaccine in symptomless HIV-1 infection. Lancet 1996, 348:1547-1551.
15. Stanley SK, Ostrowski MA, Justement JS, et al.: Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. N Engl J Med 1996, 334:1222-1230.
16. Carpenter CC, Fischl MA, Scott MH, et al.: Antiretroviral therapy for HIV infection in 1996. JAMA 1996, 276:146-154.
17. Veenstra J, Williams IG, Colebunders R, et al.: Immunization with recombinant p17/p24:Ty virus-like particles in human immunodeficiency virus-infected persons. J Infect Dis 1996, 174:862-866.
18. Schuitemaker H, Koot M, Kootstra NA, et al.: Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus populations. J Virol 1992, 66:1354-1360.
19. Lubeck MD, Natuk R, Myagkikh M, et al.: Long term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization. Nature Med 1997, 3:651-658.
20. Boyer JD, Ugen KE, Wang B, et al.: Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination. Nature Med 1997, 3:526-532.
21. Mellors JW, Rinaldo CR, Gupta P, White RM, Todd JA, Kingsley LA: Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996, 272:1167-1170.
22. Pantaleo G: How immune-based interventions can change HIV therapy. Nature Med 1997, 3:483-486.
23. Borrow P, Lewicki H, Wei X, et al.: Antiviral pressure exerted by HIV-1 specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nature Med 1997, 3:205-211.
24. Goulder PJR, Phillips RE, Colbert RA, et al.: Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nature Med 1997, 3:212-217.